Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Therapies | DelveInsight
View original at finance.yahoo.comHemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Therapies | DelveInsight The dynamics of the hemophilia A market are expected to change mainly due to the increase in prev…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
HEMLIBRA's growth curve (US Q1 2025 year-over-year sales) in the United States was flat, indicating increased competition from newer therapies
80% confidenceThe total number of diagnosed prevalent cases of Hemophilia A in the 7MM was around 49,500 in 2024
80% confidenceIn the 7MM, the highest diagnosed prevalent cases of Hemophilia A were in the United States, accounting for nearly 14,900 cases in 2024
80% confidenceHEMLIBRA has emerged as a first-line prophylactic therapy for Hemophilia A patients with inhibitors
80% confidenceThe market size for hemophilia A was found to be USD 12.2 billion in the leading markets in 2024
80% confidenceGiroctocogene fitelparvovec gene therapy for hemophilia A has demonstrated promising results in late-stage trials, significantly reducing bleeding episodes and outperforming traditional treatments
80% confidenceImmune tolerance induction (ITI) therapy continues to be the gold standard for Hemophilia A patients with inhibitors
80% confidenceThe diagnosed prevalence of Hemophilia A is expected to rise from 49K in 2024 to 50K by 2034
80% confidenceImproved diagnostic capabilities and increased disease awareness mainly drive the increase in hemophilia A cases
80% confidenceHemophilia management is shifting toward extended half-life factor therapies and cutting-edge modalities, including siRNA agents, bispecific antibodies, and gene therapy
80% confidenceThe dynamics of the hemophilia A market are expected to change mainly due to the increase in prevalence and the launch of upcoming therapies during the forecast period
80% confidenceThe United States accounted for approximately 48% of the total hemophilia A treatment market size in the 7MM in 2024
80% confidenceThe hemophilia A market is expected to exhibit growth at a CAGR of 2.9% during the forecast period (2025-2034)
80% confidenceThe anticipated launch of emerging therapies are poised to transform the hemophilia A market landscape in the coming years
80% confidence